ANTI-INFLAMMATORY DRUGS MARKET ANALYSIS

Anti-inflammatory drugs are the class of analgesics, which are used to treat multisystem inflammatory disorders. These drugs are used to relieve pain, reduce inflammation, or treat fever. These drugs are used worldwide on prescriptions as well as off label in tablets, capsules, creams, liquids, injections, sprays, and suppositories. Moreover, increasing incidence of acute and chronic diseases are expected to boost the market growth. For instance, according to an article published by the National Kidney Foundation Inc. in November 2019, reports that the prevalence of gout in the U.S. has been doubled since 1990s and now estimated that 3.9% i.e. 8.3 million adults in the U.S. had gout, amongst which 6.1 million were men and 2.2 million were women.

The global anti-inflammatory drugs market is estimated to be valued at US$ 79,830.2 million in 2020 and is expected to exhibit a CAGR of 8.6% during the forecast period (2020-2027).

Figure 1. Global Anti-inflammatory Drugs Market Share (%), by Region, 2020

To learn more about this report, request a free sample copy

Ongoing research and development for the anti-inflammatory drugs is expected to propel growth of the global anti-inflammatory drugs market

Continuous research and development followed by approvals and launches of the anti-inflammatory drugs are expected to boost the market growth over the forecast period. For instance, in April 2020, InDex Pharmaceuticals Holding AB, received positive responses from the U.S. Food and Drug Administration (U.S. FDA) and European Medicines Agency (EMA) about the phase III trial of TLR9 agonist cobitolimod. This drug is a potential new medication for patients with active moderate to severe ulcerative colitis, a chronic inflammatory bowel disease.

However, failure of drug results in the clinical trial is expected to hinder the market growth over the forecast period. For instance, in July 2020, F. Hoffmann-La Roche AG, multinational healthcare company announced that its COVACTA trial of Actemra (tocilizumab), anti-inflammatory drug failed to meet its primary endpoint of improvement. The drug was supposed to support the patients who were hospitalized with severe COVID-19 pneumonia but failed as it proved ineffective and failed to improve outcomes in the disease.

Figure 2. Global Anti-inflammatory Drugs Market Share (%), by Drug Type, 2020

To learn more about this report, request a free sample copy

Increasing cases of acute and chronic diseases in North America is expected to boost the market growth

North America is expected to hold dominant position in the global anti-inflammatory drugs market, owing to increasing new cases of acute and chronic diseases in this region. For instance, according to an article published by the Arthritis Foundation in 2017, reports that the number of adults in the U.S. with doctor-diagnosed arthritis is estimated to increase by 49% to reach 78.4 million (25.9% of all adults) by 2040.

Global Anti-inflammatory Drugs Market – Impact of Coronavirus (COVID-19) Pandemic

The coronavirus (COVID-19) pandemic and lockdowns in various countries across the globe have impacted the financial status of businesses in all sectors. The private healthcare is one such sector which has been impacted significantly by the COVID-19 pandemic.

The lockdown in various countries due to the pandemic has placed an economic burden on the healthcare sector. Moreover, the coronavirus pandemic has hampered the development, production, and supply of drugs and other healthcare products and affected growth of healthcare businesses of various companies across the globe.

As a result, the impact of the COVID-19 pandemic is also expected to limit growth of the global anti-inflammatory drugs market during the forecast period.

Key Players

Major players operating in the global anti-inflammatory drugs market include Pfizer, Inc., GlaxoSmithKline plc, Johnson & Johnson Services Inc., Merck & Company, Inc., Novartis AG, Amgen, Inc., AstraZeneca plc, Eli Lily and Company, AbbVie Inc., F. Hoffmann-La Roche AG, Bristol Myers Squibb Company, Biogen Inc., Sun Pharmaceutical Industries Ltd, Mylan, Inc., Aurobindo Pharma Limited, and Dr. Reddy’s Laboratories among others.